NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases
Key Highlights
- ➤Amir Heshmatpour purchased 80,000 NeOnc shares for $269,082 at approximately $3.36 each
- ➤Heshmatpour accumulated 271,000 shares through open-market purchases during 2026
- ➤NEO100 six-month progression-free survival reached 48.9% versus a 20% benchmark
- ➤NEO100 median overall survival was 26.1 months in recurrent high-grade glioma
- ➤NeOnc will present NEO100 and NEO212 data on November 13
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc.
“I’ve invested more than $1 million of my own money in NeOnc shares this year. I’ve added to my position repeatedly because I believe in the long-term potential of NEO100 and NEO212 for patients with brain cancer. These purchases deepen my personal investment alongside our shareholders.”
CALABASAS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, today announced that Amir F. Heshmatpour, its Executive Chairman, President and Chief Executive Officer, purchased 80,000 shares of NeOnc common stock on the open market on November 5, 6 and 9, 2026. The purchases totaled $269,082 based on reported prices, at a weighted average of approximately $3.36 per share. Heshmatpour used personal funds, and the Company issued no shares in connection with the transactions.
Heshmatpour has accumulated 271,000 shares through open-market purchases across April, May, August, September and November 2026, based on his SEC Form 4 filings and the brokerage confirmation for his November 9 purchase. He purchased 191,000 of those shares for approximately $688,000 following NeOnc’s August 12 announcement of topline Phase 2a results for intranasal NEO100.
Get started
Create a free account to read the full story.